Zobrazeno 1 - 10
of 714
pro vyhledávání: '"Byung-wan Lee"'
Autor:
Jun Sung Moon, Shinae Kang, Jong Han Choi, Kyung Ae Lee, Joon Ho Moon, Suk Chon, Dae Jung Kim, Hyun Jin Kim, Ji A Seo, Mee Kyoung Kim, Jeong Hyun Lim, Yoon Ju Song, Ye Seul Yang, Jae Hyeon Kim, You-Bin Lee, Junghyun Noh, Kyu Yeon Hur, Jong Suk Park, Sang Youl Rhee, Hae Jin Kim, Hyun Min Kim, Jung Hae Ko, Nam Hoon Kim, Chong Hwa Kim, Jeeyun Ahn, Tae Jung Oh, Soo-Kyung Kim, Jaehyun Kim, Eugene Han, Sang-Man Jin, Jaehyun Bae, Eonju Jeon, Ji Min Kim, Seon Mee Kang, Jung Hwan Park, Jae-Seung Yun, Bong-Soo Cha, Min Kyong Moon, Byung-Wan Lee
Publikováno v:
Diabetes & Metabolism Journal, Vol 48, Iss 4, Pp 546-708 (2024)
Externí odkaz:
https://doaj.org/article/1ca1a0c775dc4613bbda82213581a6e5
Publikováno v:
Diabetes & Metabolism Journal, Vol 48, Iss 3, Pp 418-428 (2024)
Background To investigate the real-world safety and effectiveness of dulaglutide in Korean adults with type 2 diabetes mellitus (T2DM). Methods This was a real-world, prospective, non-interventional post-marketing safety study conducted from May 26,
Externí odkaz:
https://doaj.org/article/dc6bebb1f5674b9da0126cbd687d27c8
Publikováno v:
Gut and Liver, Vol 18, Iss 3, Pp 509-519 (2024)
Background/Aims: Reports on the association between sarcopenic visceral obesity and non-alcoholic fatty liver disease (NAFLD)-associated morbidities remain scarce. We investigated the association between sarcopenia and visceral obesity, and the influ
Externí odkaz:
https://doaj.org/article/455dc4dceb1b4ecf9b2dba4484ca9454
Autor:
Kyung Ah Han, Yong Hyun Kim, Doo Man Kim, Byung Wan Lee, Suk Chon, Tae Seo Sohn, In Kyung Jeong, Eun-Gyoung Hong, Jang Won Son, Jae Jin Nah, Hwa Rang Song, Seong In Cho, Seung-Ah Cho, Kun Ho Yoon
Publikováno v:
Diabetes & Metabolism Journal, Vol 47, Iss 6, Pp 796-807 (2023)
Background Enavogliflozin is a novel sodium-glucose cotransporter-2 inhibitor currently under clinical development. This study evaluated the efficacy and safety of enavogliflozin as an add-on to metformin in Korean patients with type 2 diabetes melli
Externí odkaz:
https://doaj.org/article/de916f00723347d8939b4e042557d251
Autor:
Byung Wan Lee, KyungWan Min, Eun-Gyoung Hong, Bon Jeong Ku, Jun Goo Kang, Suk Chon, Won-Young Lee, Mi Kyoung Park, Jae Hyeon Kim, Sang Yong Kim, Keeho Song, Soon Jib Yoo
Publikováno v:
Endocrinology and Metabolism, Vol 38, Iss 3, Pp 328-337 (2023)
Background This study evaluated the efficacy and safety of add-on gemigliptin in patients with type 2 diabetes mellitus (T2DM) who had inadequate glycemic control with metformin and dapagliflozin. Methods In this randomized, placebo-controlled, paral
Externí odkaz:
https://doaj.org/article/87d77379d1ae4e529a0ebf5b900369c8
Autor:
Sejeong Lee, Jaehyun Bae, Seung Up Kim, Minyoung Lee, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2024)
AimHepatic ketogenesis is a key metabolic pathway that regulates energy homeostasis. Some related controversies exist regarding the pathogenesis of metabolic-associated fatty liver disease (MAFLD). We aimed to investigate whether intact ketogenic cap
Externí odkaz:
https://doaj.org/article/2869af4844d34245ad8fc77ff0a1329b
Autor:
Eugene Han, Yong-ho Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Seung Up Kim
Publikováno v:
Gut and Liver, Vol 16, Iss 5, Pp 786-797 (2022)
Background/Aims: Metabolic dysfunction associated fatty liver disease (MAFLD) has recently been introduced to compensate for the conventional concept of nonalcoholic fatty liver disease (NAFLD). We explored whether fibrotic burden determines the risk
Externí odkaz:
https://doaj.org/article/15bdfa0e836d4ce8aeb3e9f4887ed1b1
Autor:
Jong Ha Baek, Ye Seul Yang, Seung-Hyun Ko, Kyung Do Han, Jae Hyeon Kim, Min Kyong Moon, Jong Suk Park, Byung-Wan Lee, Tae Jung Oh, Suk Chon, Jong Han Choi, Kyu Yeon Hur
Publikováno v:
Diabetes & Metabolism Journal, Vol 46, Iss 5, Pp 701-712 (2022)
Background To evaluate prescription trends and clinical factors of the sodium-glucose cotransporter 2 inhibitors (SGLT2i) use according to the presence of atherosclerotic cardiovascular disease (ASCVD) or heart failure (HF) in Korean patients with ty
Externí odkaz:
https://doaj.org/article/87ddde7c96524004afd813e104cb4206
Autor:
Gian Paolo Fadini, Giovanni Targher, Masahide Hamaguchi, Herbert Tilg, Seung Up Kim, Dan-Qin Sun, Xuhong Hou, Jianghua Zhou, Christopher D Byrne, Byung-wan Lee, Masato Furuhashi, Ning-Jian Wang
Publikováno v:
eGastroenterology, Vol 1, Iss 1 (2023)
Background and aim Metabolic dysfunction-associated fatty liver disease (MAFLD) is an alternative description and classification of non-alcoholic fatty liver disease (NAFLD) that may have better utility than NAFLD in clinical practice. We performed a
Externí odkaz:
https://doaj.org/article/63a6f9538f874914ae97401e9544541f
Autor:
Jaehyun Bae, Ji Young Lee, Eugene Shin, Minyoung Lee, Yong-ho Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-8 (2022)
Abstract The α-glucosidase inhibitor (α-GI) delays the intestinal absorption of glucose, which reduces postprandial hepatic glucose intake. This mechanism is considered to be effective in treating non-alcoholic fatty liver disease (NAFLD). Here, we
Externí odkaz:
https://doaj.org/article/d836661f375c45c99aff1ad618050d41